We demonstrate that, while awaiting the results of RARa-fusions testing, the entities “APL-like” NPM1m AML and acute promyelocytic leukemia (APL) can be distinguished based on specific hematologic indices (DDs/WBC ratio and PT/WBC ratio for non-anticoagulated patients), as well as the expression of CD4 and CD64. This evidence concerns the gene FCGR1A and acute myeloid leukemia.